StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid

HCID 54585
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
80573-04-2
Standard-SMILES
O=C(O)CCNC(=O)c1ccc(N=Nc2ccc(O)c(C(=O)O)c2)cc1
InChIKey
IPOKCKJONYRRHP-UHFFFAOYSA-N
Summenformel
C17H15N3O6
Durchschnittliche Molmasse
357,32 g/mol
Monoisotopische Masse
357,0960852

Überblick

Balsalazide is a monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-beta-alanine via an azo bond. It has a role as a non-steroidal anti-inflammatory drug, an anti-ulcer drug, a prodrug and a gastrointestinal drug. It is a conjugate acid of a balsalazide(2-).

Namen und Bezeichner

Bevorzugter Name
5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid
IUPAC
5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid
Englischer Name
Balsalazide
Summenformel
C17H15N3O6
Molmasse
357.32

Namen und Synonyme

5-((4-((2-carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acidDTXSID508610275-({4-[(2-Carboxyethyl)carbamoyl]phenyl}diazenyl)-2-hydroxybenzoic acidRefChem:1072307DTXCID10810339BALSALAZIDE80573-04-2BalsalazidoBalsalazidaBalsalazidumBalsalazidum [Latin]Balsalazida [Spanish]
Weitere Namen anzeigen
CS-1360BalsalazineBalsalazide D4Balsalazide 98%BALSALAZIDE SODIUM
Balsalazido [Spanish](E)-5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acidColazalGiazo(E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acidColazideBalsalazide (INN)DTXSID7040653

Datenbank-Bezeichner

CAS
80573-04-2
PubChem CID
54585
DTXSID
DTXSID50861027
ChEMBL
CHEMBL1208641

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
2,2
Polarare Oberfläche (TPSA)
149 Ų
H-Brücken-Donoren
4
H-Brücken-Akzeptoren
8
Frei drehbare Bindungen
7
Schwere Atome
26
Formalladung
0
Komplexität
545

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
SolubilityFreely soluble as disodium salt

Physikochemische Eigenschaften

Schmelzpunkt
254 · 254-255C
Siedepunkt
729.6 · 729.6±60.0 °C(Predicted)
Dichte
1.44 · 1.44±0.1 g/cm3(Predicted)
Dampfdruck
0 Pa · 0Pa at 20℃
storage temp.
-20 °C · -20°C Freezer
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
2.97 · 2.97±0.10(Predicted)
Farbe
Yellow to Beige
InChI
InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+

Chemie und Industrie

Pharmakologische Informationen

Protein Binding≥99%
Pharmacodynamics · 1 Eintrag

Balsalazide is a prodrug that has little or no pharmacologic activity until it is enzymatically cleaved in the colon to produce mesalamine (5-aminosalicylic acid), an anti inflammatory drug indicated for the treatment of mildly to moderately active ulcerative colitis. Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and the intert 4-aminobenzoyl-(beta)-alanine. As a result, the spectrum of pharmacologic activity of balsalazide is similar to that of mesalamine.

Mechanism of Action · 1 Eintrag

The mechanism of action of 5-aminosalicylic acid is unknown, but appears to exert its anti-inflammatory effects locally (in the GI tract) rather than systemically. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (catalyzes the formation of prostaglandin precursors from arachidonic acid), and through the lipoxygenase pathways (catalyzes the formation of leukotrienes and hydroxyeicosatetraenoic acids from arachidonic acid and its metabolites), is increased in patients with chronic inflammatory bowel disease. Therefore, it is possible that 5-aminosalicylic acid diminishes inflammation by blocking production of arachidonic acid metabolites in the colon through both the inhibition of cyclooxygenase and lipoxygenase.

Biological Half-LifeHalf-life could not be determined.
Metabolism/MetabolitesCleaved in the colon via bacterial azoreduction to 5–aminosalicylic acid (5–ASA) and 4–aminobenzoyl-beta-alanine, the inactive carrier moiety.
Absorption, Distribution and Excretion · 2 Einträge

Low and variable, intact balsalazide is poorly absorbed systemically.

The products of the azoreduction of this compound, 5-ASA and 4-aminobenzoyl-ß-alanine, and their N-acetylated metabolites have been identified in plasma, urine and feces. Following single-dose administration of 2.25 g COLAZAL (three 750 mg capsules) under fasting conditions in healthy subjects, mean urinary recovery of balsalazide, 5-ASA, and N-Ac-5-ASA was 0.20%, 0.22% and 10.2%, respectively.

Zugehörige Reaktionen

5
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 916723
HRID 916723als Produkt
Reaktionsgleichung von HRID 1750338
HRID 1750338als Edukt
Reaktionsgleichung von HRID 2202207
HRID 2202207als Edukt
Reaktionsgleichung von HRID 2205960
HRID 2205960als Edukt
Reaktionsgleichung von HRID 2272552
HRID 2272552als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
ChEBI
CHEBI:267413
UNII
P80AL8J7ZP
InChIKey
IPOKCKJONYRRHP-FMQUCBEESA-N
SMILES
C(O)(=O)C1=CC(/N=N/C2=CC=C(C(NCCC(O)=O)=O)C=C2)=CC=C1O
LogP
1 at · 1 at 25℃ and pH7.5
EPA chemische Informationen
5 · Benzoic acid, 5-[(1E)-2-[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]diazenyl]-2-hydroxy- (80573-04-2)
Anwendungen · 2 Einträge

BeschreibungBalsalazide is a prodrug form of 5-aminosalicylic acid (5-ASA; ). It is cleaved by bacterial azoreductases in the intestinal lumen to release 5-ASA. Balsalazide (600 mg/kg per day) decreases IL-2 levels and increases IL-6 levels in the serum and colonic mucosa membrane, as well as decreases micro- and macroscopic colonic damage, in a rat model of colitis induced by 2,4-dinitrochlorobenzene (DNCB). Formulations containing balsalazide have been used in the treatment of ulcerative colitis.

VerwendenAn analogue of Sulfasalazine, A prodrug of 5-Aminosalicylic Acid

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

NatriumnitritL-Alanin4-NitrobenzoylchloridSalicylsäure

Ergänzende Hinweise

DefinitionChEBI: A monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-beta-alanine via an azo bond.